DED drop study success
Aerie Pharmaceuticals announced significant increases in tear production in the phase 2b study of its dry-eye disease (DED) drops AR-15512, which it says also create a cooling sensation on the
Staff reporters1 min read
Dry Eye
TearCare for MGD bags FDA approval
Sight Sciences’ TearCare system for the treatment of meibomian gland dysfunction (MGD) has received the US Food and Drug Administration’s (FDA) 510(K) device clearance. Designed for adult patients
Staff reporters1 min read
CORE update: DED and digital device use
The Centre for Ocular Research and Education (CORE) has released an update exploring whether increasing use of screens affects ocular comfort and can ultimately lead to dry eye
Staff reporters1 min read
Eyestil Synfo drops for DED hit NZ
Medix 21 Surgical has introduced SIFI’s Eyestil Synfo moisturising eye drops for dry eye disease (DED) in New Zealand.
Staff reporters1 min read
FDA-approved OptiLight unveiled
Lumenis showcased its new OptiLight technology for the treatment of dry eye disease (DED) to the Australian and New Zealand market at a recent virtual event, sharing insights into its application for clinics and their patients.
Staff reporters2 min read
Trial success for DED drops
US-based Aldeyra Therapeutics announced it’s 0.25% reproxalap ophthalmic solution met its primary endpoint in a phase 2 clinical trial in dry eye disease (DED) patients. Of the 158 patients enrolled
Staff reporters1 min read
Improved gland transplantation technique for severe DED
A modified technique for minor salivary gland transplantation (MSGT) as a treatment for severe dry eye disease (DED) led to long-term improvements in visual acuity, ocular surface environment and
Staff reporters2 min read
DED drug misses endpoint
Ocular Therapeutix said a phase-2 study of its OTX-CSI insert for the treatment of dry-eye disease (DED) missed its primary endpoint of increased tear production. The US-based clinical trial was
Staff reporters1 min read
Ciclosporin gains public funding in Australia
Ciclosporin (Ikervis) has been listed on the Pharmaceutical Benefits Scheme (PBS) in Australia, saving around 7,500 severe keratitis patients with dry eye disease (DED) an estimated A$900 each per year, said Greg Hunt, Minister for Health and Aged Care.
Staff reporters2 min read
Adverse effects of cancer therapy on the ocular surface and anterior segment
With a large (and growing) number of New Zealanders undergoing cancer therapy, eyecare professionals should be cognisant of the ocular complications that can result from many of these treatments to ensure their timely and appropriate diagnosis and management. Although chemotherapy remains a mainstay
Dr Isabella Cheung7 min read
DED nasal spray secures FDA approval
Oyster Point Pharma has received US FDA approval for Tyrvaya (varenicline) nasal spray for dry eye disease (DED). "The approval of Tyrvaya nasal spray marks a milestone for patients and eyecare
Staff reporters2 min read
OptiLight secures FDA approval
Lumenis has received the US Food and Drug Administration’s (FDA) De Novo authorisation for its newest intense pulsed light (IPL) device OptiLight, designed to improve signs of dry eye
Staff reporters2 min read